Case Report: Early Association of Vemurafenib to Standard Chemotherapy in Multisystem Langerhans Cell Histiocytosis in a Newborn: Taking a Chance for a Better Outcome?

Case Report: Early Association of Vemurafenib to Standard Chemotherapy in Multisystem Langerhans Cell Histiocytosis in a Newborn: Taking a Chance for a Better Outcome?

Langerhans cell histiocytosis (LCH) is due to aberrant monoclonal proliferation and accumulation of dendritic cells, ranging from a self-limiting local condition to a rapidly progressive multisystem disease with poor prognosis. Pathogenic cells originate from a myeloid-derived precursor characterize...

Full description

Bibliographic Details
Main Authors: Stefania Gaspari, Valentina Di Ruscio, Francesca Stocchi, Roberto Carta, Marco Becilli, Maria Antonietta De Ioris
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-12-01
Series:Frontiers in Oncology
Subjects:
target therapy
Langerhans cell histiocytosis
Vemurafenib
multisystem disease
newborn
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.794498/full

Similar Items

Similar Items